Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depressive Disorder, NOS Clear all
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Peoria, Arizona • Pasadena, California • San Diego, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 25, 2026, 10:48 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

NCT03093025
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TS-121 10 mg, TS-121 50 mg, Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Phase 3 Interventional

Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response

NCT00285376
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
vilazodone
Drug
Lead sponsor
Genaissance Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Alamitos, California • Newport Beach, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Not applicable Interventional

Effectiveness of Culturally Based Congruent Care in Treating Hispanics With Major Depressive Disorder

NCT00247195
View directory record Official record
Conditions
Depression
Interventions
Culturally Congruent Assessment and Treatment
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D Supplementation and Effects on Mood in Emergency Medicine Residents

NCT03739671
View directory record Official record
Conditions
Seasonal Mood Disorder
Interventions
Vitamin D, No Vitamin D
Dietary Supplement
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease

NCT00304161
View directory record Official record
Conditions
Depressive Disorder, Parkinson Disease
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 79 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 25, 2026, 10:48 AM EDT
Recruiting Not applicable Interventional

Closed-Loop Deep Brain Stimulation for Major Depression

NCT04004169
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Stimulation-ON, Stimulation-OFF, Stimulation-ON Active Control
Device
Lead sponsor
Andrew Krystal
Other
Eligibility
22 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 25, 2026, 10:48 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 25, 2026, 10:48 AM EDT
Recruiting Not applicable Interventional

Remote Evaluation and Alerting for Collaborative Health (REACH) in Depression

NCT07174557
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
MoodTriggers Application
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Hanover, New Hampshire • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 25, 2026, 10:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

NCT00579267
View directory record Official record
Conditions
Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions
MINI-KID
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2009 · Synced Sep 25, 2026, 10:48 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Tracking Brain Biomarkers and Renormalization Associated With Antidepressant Transcranial Magnetic Stimulation Therapy

NCT06043401
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Neuroimaging with Magnetic Resonance Imaging (MRI)
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Not applicable Interventional

Multifaceted Depression and Cardiovascular Program

NCT02069912
View directory record Official record
Conditions
Depression, Depressive Disorder, Behavioral Symptoms, Mood Disorders
Interventions
Collaborative depression care management
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 25, 2026, 10:48 AM EDT
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

NCT00252330
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SR58611A
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)

NCT00385307
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
amibegron (SR58611A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 25, 2026, 10:48 AM EDT
Completed No phase listed Observational

Using Neuroimaging to Investigate Major Depressive Disorder

NCT00781677
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Anxiety
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Not applicable Interventional Results available

Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature

NCT05535062
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
Neuronetics
Other
Eligibility
22 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

A Study in Relapse Prevention of Treatment-Resistant Depression

NCT00958568
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Olanzapine and Fluoxetine combination (OFC), Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
36
States / cities
Pasadena, California • Sherman Oaks, California • Wildomar, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Sep 25, 2026, 10:48 AM EDT
Terminated Phase 3 Interventional

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

NCT06514742
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
39
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Not applicable Interventional

Sleep To Reduce Incident Depression Effectively

NCT03322774
View directory record Official record
Conditions
Insomnia, Primary, Major Depressive Disorder, Rumination
Interventions
digital Cognitive Behavioral Therapy for Insomnia, face-to-face Cognitive Behavioral Therapy for Insomnia, Sleep Hygiene Education Control
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
1,237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State

NCT00490542
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Depression
Interventions
ziprasidone (Geodon), placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Cambridge, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 25, 2026, 10:48 AM EDT
Completed Not applicable Interventional

Adapting Cognitive Behavioral Therapy (CBT) for Chinese Americans

NCT01786746
View directory record Official record
Conditions
Major Depression
Interventions
cognitive behavioral therapy, culturally adapted cognitive behavioral therapy
Behavioral
Lead sponsor
Claremont McKenna College
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Claremont, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 25, 2026, 10:48 AM EDT
Recruiting Phase 2 Interventional

Stratified Pharmacological Approaches for Regulating Circuit-Level Effects

NCT07022405
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Pramipexole Immediate Release
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 25, 2026, 10:48 AM EDT